Roche's Divarasib Meets Primary Endpoint In Phase 3 Krascendo 1 Study For Treating Lung Cancer

Roche announced its Phase 3 Krascendo 1 trial for the KRAS12C inhibitor Divasarib met its primary and key secondary endpoints in non-small cell lung cancer versus sotorasib and adagrasib, signaling clinical efficacy progress. The positive Phase 3 readout is a meaningful potential catalyst for the program, though specific magnitude (e.g., OS/PFS gains) was not provided in the report.

Analysis

Roche announced its Phase 3 Krascendo 1 trial for the KRAS12C inhibitor Divasarib met its primary and key secondary endpoints in non-small cell lung cancer versus sotorasib and adagrasib, signaling clinical efficacy progress. The positive Phase 3 readout is a meaningful potential catalyst for the program, though specific magnitude (e.g., OS/PFS gains) was not provided in the report.